Aduro Biotech Abstracts Accepted for Presentation at the 2019 American Society of Clinical Oncology Annual Meeting
April 17 2019 - 3:05PM
Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical stage
biopharmaceutical company developing therapies in the Stimulator of
Interferon Genes (STING) and A Proliferation Inducing Ligand
(APRIL) pathways, today announced that abstracts pertaining to the
company’s lead programs, STING agonist ADU-S100 and anti-APRIL
antibody BION-1301, will be presented at the upcoming 2019 American
Society of Clinical Oncology (ASCO) Annual Meeting, which will be
held May 31 to June 4, 2019 at the McCormick Place Convention
Center in Chicago, Illinois.
Details of the oral presentation are as follows:
ADU-S100
(MIW815) |
|
Abstract
2507: |
Phase Ib study of
MIW815 (ADU-S100) in combination with spartalizumab (PDR001) in
patients (pts) with advanced/metastatic solid tumors or
lymphomas. |
Presenter: |
Dr. Funda Meric-Bernstam,
MD Anderson Cancer Center |
Session: |
Oral Abstract Session:
Developmental Immunotherapy and Tumor Immunobiology |
Date/Time/Location: |
Sunday, June 2, 2019, 8:00
AM – 11:00 AM CDT in Hall D2 |
Details of the poster presentations are as follows:
BION-1301 |
|
Abstract 8012 /
Poster Board #338: |
Safety and
tolerability of BION-1301 in adults with relapsed or refractory
multiple myeloma. |
Presenter: |
Dr. William Bensinger,
Fred Hutchinson Cancer Research Center |
Session: |
Poster Discussion Session:
Hematologic Malignancies – Plasma Cell Dyscrasia |
Date/Time/Location: |
Poster Display: Monday,
June 3, 2019, 8:00 AM – 11:00 AM CDT in Hall A |
|
Poster Discussion: Monday,
June 3, 2019, 1:15 PM – 2:45 PM CDT in E450 |
|
|
Abstract 8022 /
Poster Board #348: |
Pharmacokinetics,
pharmacodynamics, safety, and tolerability of BION-1301
in adults with relapsed or refractory
multiple myeloma. |
Session: |
Poster Session:
Hematologic Malignancies – Plasma Cell Dyscrasia |
Date/Time/Location: |
Poster Display: Monday
June 3, 2019, 8:00 AM – 11:00 AM CDT in Hall A |
About AduroAduro Biotech, Inc. is a
clinical-stage biopharmaceutical company focused on the discovery,
development and commercialization of therapies that are designed to
harness the body's natural immune system for the treatment of
patients with challenging diseases. Aduro’s product candidates in
the Stimulator of Interferon Genes (STING) and A Proliferation
Inducing Ligand (APRIL) pathways are being investigated in cancer,
autoimmune and inflammatory diseases. ADU-S100 (MIW815), which
potentially activates the intracellular STING receptor for a potent
tumor-specific immune response, is being evaluated in patients with
cutaneously accessible metastatic solid tumors or lymphomas.
BION-1301, a fully blocking monoclonal antibody that blocks APRIL
binding to both the BCMA and TACI receptors, is being evaluated in
multiple myeloma and as a potential treatment for IgA nephropathy.
Aduro is collaborating with a number of leading global
pharmaceutical companies to help expand and drive its product
pipeline. For more information, please visit www.aduro.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for purposes
of the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements include statements
regarding our intentions or current expectations concerning, among
other things, the potential for our technology. In some cases, you
can identify these statements by forward-looking words such as
“may,” “will,” “continue,” “anticipate,” “intend,” “could,”
“project,” “expect” or the negative or plural of these words or
similar expressions. Forward-looking statements are not
guarantees of future performance and are subject to risks and
uncertainties that could cause actual results and events to differ
materially from those anticipated, including, but not limited to,
early or preliminary clinical trial results may not be predictive
of future results, our history of net operating losses and
uncertainty regarding our ability to achieve profitability, our
ability to develop and commercialize our product candidates, our
ability to use and expand our technologies to build a pipeline of
product candidates, our ability to obtain and maintain regulatory
approval of our product candidates, our ability to operate in a
competitive industry and compete successfully against competitors
that have greater resources than we do, our reliance on third
parties, and our ability to obtain and adequately protect
intellectual property rights for our product candidates. We
discuss many of these risks in greater detail under the heading
“Risk Factors” contained in our annual report on Form 10-K for the
year ended December 31, 2018, which is on file with the Securities
and Exchange Commission. Any forward-looking statements that we
make in this press release speak only as of the date of this press
release. We assume no obligation to update our forward-looking
statements whether as a result of new information, future events or
otherwise, after the date of this press release.
Investor
Relations Contact: |
Media
Contact: |
Noopur
Liffick |
Aljanae
Reynolds |
510-809-2465 |
510-809-2452 |
investors@aduro.com |
press@aduro.com |
Aduro Biotech (NASDAQ:ADRO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aduro Biotech (NASDAQ:ADRO)
Historical Stock Chart
From Jul 2023 to Jul 2024